Reuters logo
BRIEF-VBL Therapeutics reports positive review of late-stage trial for glioblastoma drug
April 20, 2017 / 8:23 PM / in 8 months

BRIEF-VBL Therapeutics reports positive review of late-stage trial for glioblastoma drug

April 20 (Reuters) - Vascular Biogenics Ltd-

* VBL Therapeutics announces positive dsmc review in phase 3 globe trial investigating vb-111 in RGBM

* Vascular Biogenics Ltd - currently expect globe trial interim analysis to occur in mid-2017

* Vascular Biogenics Ltd - top-line results from full dataset to be available in early 2018.

* Vascular Biogenics - committee reviewed globe safety data and unanimously recommended that study continue as planned

* Vascular Biogenics - committee reviewed globe safety data and unanimously recommended that study continue as planned Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below